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A mutation in codon 122 of the mouse p53 gene resulting in a T to L amino acid substitution (T122?L) is frequently associated with skin cancer in UV-irradiated mice that are both homozygous mutant for the nucleotide excision repair (NER) gene Xpc (Xpc
7/7
) and hemizygous mutant for the p53 gene. We investigated the functional consequences of the mouse T122?L mutation when expressed either in mammalian cells or in the yeast Saccharomyces cerevisiae. Similar to a non-functional allele, high expression of the T122?L allele in p53 7/7 mouse embryo fibroblasts and human Saos-2 cells failed to suppress growth. However, the T122?L mutant p53 showed wild-type transactivation levels with Bax and MDM2 promoters when expressed in either cell type and retained transactivation of the p21 and the c-Fos promoters in one cell line. Using a recently developed rheostatable p53 induction system in yeast we assessed the T122?L transactivation capacity at low levels of protein expression using 12 different p53 response elements (REs). Compared to wild-type p53 the T122?L protein manifested an unusual transactivation pattern comprising reduced and enhanced activity with specific REs. The high incidence of the T122?L mutant allele in the Xpc 7/7 background suggests that both genetic and epigenetic conditions may facilitate the emergence of particular functional p53 mutations. Furthermore, the approach that we have taken also provides for the dissection of functions that may be retained in many p53 tumor alleles.
Introduction
The tumor suppressor gene p53 plays an important role in maintaining genome integrity (Prives and Hall, 1999) . Upon stabilization and activation, which are achieved mainly by post-translational modifications (Meek, 1999) , p53 protein can act in the homotetrameric conformation as a sequence-specific transcription factor (McLure and Lee, 1998) . Transactivation is the best characterized and probably most relevant function among the many biochemical activities ascribed to p53 protein (Ko and Prives, 1996) . p53-response elements (REs) corresponding to a rather loose consensus sequence (two variably spaced palindromic decamers of 5'-RRRCWWGYYY each binding to a p53 dimer) (el-Deiry et al., 1992) have been identified in promoter and intronic regions of over 50 genes. The growing list of p53-regulated genes includes p21, GADD45, p53 -R2, FAS, Bax, PIG3, IGF -BP3, Killer/DR5, AIP1 and MDM2 (Ashcroft and Vousden, 1999; el-Deiry, 1998; Oda et al., 2000; Tanaka et al., 2000) . The products of these genes are involved in cell cycle control, induction of apoptosis, modulation of DNA repair, differentiation, senescence, and control of p53 stability/activity.
Recent studies have further validated the view that p53 is a tightly controlled cellular secondary sensor that can integrate many different signals and that regulates the expression of a large number of genes with variable kinetics and intensity (Vogelstein et al., 2000; Yu et al., 1999; Zhao et al., 2000) . This key role in signal transduction predicts a strong selection for p53 inactivation in tumors and supports the notion that loss of p53 function disrupts basic cellular functions. An issue that has received relatively little attention is that partial inactivation of p53 activity may be sufficient for, or even favor, tumor progression, depending on the cell type and physiological state, and the precise function of the mutant p53 allele in question.
The p53 gene is frequently (450%) mutated during tumorigenesis (Hainaut and Hollstein, 2000) . About 80% of p53 tumor mutations are missense and result in single amino acid changes that are predicted to interfere with DNA binding and hence impair transactivation (Ko and Prives, 1996) . Some mutations can be dominant-negative leading to partially inactive heterotetramers (Aurelio et al., 2000; Brachmann et al., 1996) , a feature that may explain the unusual predominance of missense changes in the p53 tumor mutation spectrum (Hernandez-Boussard et al., 1999) .
Several recent studies support the view that certain p53 mutant alleles can retain partial function. Some mutations are associated with partial transactivation and are capable of inducing G1 arrest, but not apoptosis (Ludwig et al., 1996; Munsch et al., 2000) . Furthermore, a recent analysis of 77 different p53 mutant proteins from tumors revealed that 415% could still activate a yeast promoter containing a p21 RE, but not the Bax or PIG3 RE (Campomenosi et al., 2001) , which presumably is important in tumor development. The observation that deletion of the p21 gene does not result in increased spontaneous tumor development and can even decrease tumorigenesis (Pantoja and Serrano, 1999; Wang et al., 1997) , suggests that p53 mutant alleles that retain some transactivation capability might confer a selectable advantage over null alleles under appropriate conditions. For example, apoptosis can be prevented by expression of p21 (Gorospe et al., 1997; Suzuki et al., 2000) .
A few p53 mutant alleles appear to have acquired functions that may provide a selective advantage to tumor cells, such as the up-regulation of growth promoting genes (e.g., Myc, MDR, VEGF) (Frazier et al., 1998; Kieser et al., 1994; Lin et al., 1995) . Finally, p53 mutant alleles that appear normal for transactivation, growth suppression and apoptosis when ectopically expressed at high levels in a tumor cell line, have been detected in breast and ovarian tumors associated with BRCA1 defects (Smith et al., 1999) . Hence, detailed functional analysis of multiple tumor p53 alleles is expected to provide valuable information in predicting tumor state, including aggressiveness and responsiveness to therapy.
We recently reported that codon 122 of the mouse p53 gene is a novel hotspot for mutation in UV radiation-induced skin cancers in xeroderma pigmentosum (XP) group C mice that are also hemizygous for p53 (Xpc 7/7 p53
) . Surprisingly, the hotspot does not involve adjacent pyrimidines, the major targets for UV damage, but instead occurs at an AC site. The resulting threonine to leucine amino acid substitution (T122?L) accounted for *40% of all mutations in skin cancers from UV-irradiated Xpc 7/7 p53 +/7 mice, and was never detected in UV radiationinduced skin cancers in wild-type mice. Similarly, the T122?L mutation accounted for only 6% of p53 mutations in Xpc +/7 p53 +/7 or in Xpc 7/7 p53 +/+ mice and was also only rarely observed in Xpa 7/7 mice or mice defective in the Csa (Cokayne syndrome group A) gene required for transcription-coupled excision repair (D Nahari and EC Friedberg, unpublished observations). The origin of this mutational hotspot is not known, but is presumed to result from a non-dipyrimidine photoproduct. Its unique prevalence in skin cancers from Xpc 7/7 p53 +/7 mice suggests both that the Xpc gene product is specifically required for its repair, and that the T122?L mutation is recessive. However, the prevalence of this signature mutation uniquely in the Xpc 7/7 p53 +/7 genetic background may additionally or alternatively be determined by novel specific functional attributes of the mutant p53 protein encoded by the T122?L allele that promote its selection during carcinogenesis in the skin. Furthermore, such selection may be influenced by physiological attributes associated with the Xpc homozygous mutant state.
In order to explore the functional consequences of the T122?L mutation we have carried out ectopic expression of this mutant p53 protein in mouse embryo fibroblasts (MEFs) and in human tumor cells that are p53 null. Additionally, we have exploited a recently developed p53 functional assay in yeast ) that was adapted to precisely assess the transactivation potential of the T122?L allele with various p53 REs under conditions of variable expression. Using this sensitive assay, the T122?L allele exhibits a novel set of functional changes embracing both enhanced and reduced transactivation activity for 12 different p53 REs. We conclude that the precise pattern of T122?L p53-regulated gene expression, rather than a simple loss of p53 function, may be a critical determinant in tumor selection and progression in UV-irradiated mouse skin cells.
Results
The T122?L allele exhibits limited growth suppression in MEF and Saos-2 cells
In order to functionally characterize the murine T122?L allele in mammalian cells it was transferred into p53 7/7 MEF cells using a retroviral vector that generates high levels of p53 expression. Responses were compared with expressed wild-type p53 and an R270?C mutant allele. Mouse codon R270 and the equivalent human codon R273 are mutational hotspots in p53 that are known to inactivate p53 function in many types of tumors. Expression of wild-type p53 protein reduced the relative colony forming ability to 12% ( Figure 1a ). As expected, the R270?C allele was much less effective at causing growth suppression. Expression of the T122?L allele had an intermediate effect (65% vs 42% survival, relative to vector control), suggesting some retention of p53 function.
We also examined the effect of high expression of the T122?L allele in the human osteosarcoma-derived Saos-2 cell line which is null for both the Rb and the p53 tumor suppressor genes (Figure 1b) . Once again, wild-type p53 reduced relative colony formation while the T122?L and the R270?C alleles had less effect (70% vs 88% survival, respectively, relative to vector). Hence, as relates to growth the T122?L mutant protein has minimal residual function in both cell lines in this assay.
The expression levels of p53 protein were examined in stable MEFs and Saos-2 transformant clones obtained in a limiting dilution experiment. As expected, T122?L p53 mutational hotspot A Inga et al there was no detectable p53 in the isolates recovered from transfections with wild-type p53, while the R270?C transfectants expressed p53 protein at moderate levels ( Figure 1c,d , and data not shown). T122?L protein expression was also retained in stable MEF clones (Figure 1c ). In contrast, no p53 protein was detected in Saos-2 clones transfected with the T122?L vector (Figure 1d , five of the six clones examined are presented), suggesting that, similar to wild-type p53, the T122?L protein may not be tolerated in this cell line. Lower levels of expression from the LTR promoter compared to the CMV promoter (data not shown) may explain why stable transfectants expressing T122?L in the MEF cells could be established. However, the result is surprising since the presence of the T122?L vector had little effect on growth suppression in Saos-2 cells (Figure 1b) .
The T122?L protein retains the ability to cause DNA damage-induced G1 arrest but not apoptosis p53 +/+ and p53 7/7 MEF clones expressing either the R270?C or T122?L p53 alleles were irradiated with either 10 J/m 2 UVC or 25 J/m 2 UVB light and the number of apoptotic cells was measured 48 h later using FACS analysis. These doses resulted in different levels of both p53-dependent and -independent apoptosis (Figure 2a,b) . The p53 mutants were defective in apoptosis and exhibited levels of cell death comparable to p53 null cells (i.e., p53-independent apoptosis).
Fibroblasts manifest a preference for p53-dependent cell cycle arrest over apoptosis when DNA damage is not extensive (MacCallum et al., 1996) . Therefore, UVB radiation-induced cell cycle responses were examined in the non-apoptotic cell population 48 h after exposure to UV radiation of 25 J/m 2 . Many of the MEF cells lacking p53 were in the S phase ( Figure  2c ; black line in the top figure) , indicating that the G1 arrest was not functional and that irradiation slowed progression through the S phase, leading to an accumulation of cells in this phase of the cell cycle. Mock-irradiated p53 7/7 cells were largely in G1 at 48 h, typical for cycling cells of this MEF line (solid peaks). As expected, irradiated normal MEFs (p53 +/+ ) that express the wild-type p53 gene arrested in G1. T122?L-expressing cells similarly retained a large G1 population, consistent with retention of p53 function (Figure 2c ). In contrast, cells expressing the R270?C allele exhibited a UV-radiation response similar to p53 7/7 MEFs (data not shown). Collectively, these results suggest that unlike the R270?C allele, the T122?L allele does not result in a typical loss of function phenotype. The relative mean number and the standard deviations for three independent experiments are presented. Expression of p53 alleles in stable transfectants: puromycin resistant MEF clones (c) and G418 resistant Saos-2 clones (d) were isolated and p53 expression was determined by Western blot analyses (pAb1801 and DO-1). 50 mg of extract were loaded in each lane. Actin was used as control for MEFs extracts while the non-specific band served as control for the Saos-2
T122?L p53 protein has altered transactivation specificity
We evaluated transactivation of a luciferase reporter gene under the control of the human p21, MDM2, Bax, or c-Fos promoters, or the RGC RE. p53
7/7
MEFs were subjected to transient transfection by either the wild-type, T122?L or the R270?C alleles, along with a plasmid containing a luciferase reporter downstream from one of the p53-responsive promoters. The luciferase activity was determined in protein extracts 48 h later. The average activity relative to wild-type p53 and the standard deviation of at least three independent experiments are presented in Figure 3a .
Although the large variability in this experiment prevents a reliable assessment of subtle differences, this analysis suggests that the T122?L mutant protein exhibits an altered transactivation pattern. As expected, wild-type p53 protein was able to activate transcription from all the promoters, while R270?C was clearly deficient. The T122?L form failed to activate either the RGC cassette or the p21 promoter. Surprisingly, the protein was able to activate both the MDM2 and the weaker Bax promoter. Over-expression of wild-type p53 represses the c-Fos basal promoter (described in (Ginsberg et al., 1991) and Figure 3a ). The T122?L and the R270?C alleles failed to repress the c-Fos promoter. The first intron of the c-Fos gene also contains a p53 RE and wild-type p53 at near physiological levels of expression can activate a construct that includes the luciferase reporter gene fused to this region (Elkeles et al., 1999) . The T122?L allele, but not R270?C, activated this RE, though at reduced levels compared to wild-type p53 protein ( Figure 3a) . Consistent with the transactivation results both wild-type and mutant T122?L p53 proteins prepared from stably infected p53 7/7 MEFs bound a p53 consensus RE while R270?C protein did not (data not shown).
Transactivation of Bax, p21, RGC and MDM2 was also examined in Saos-2 cells using a similar approach, except that luciferase activity was measured in protein extracts obtained 24 h after transfection. Levels of p53 protein were high at this time and similar for all three alleles (see Figure 3b ). Results were comparable to those observed with MEFs for both the T122?L and the R270?C mutants, except that the T122?L allele also strongly activated p21 in the Saos-2 cells (data not shown). This difference between MEF and Saos-2 cells for p21 might reflect cell type-dependent effects. The level of endogenous p21 induction was measured in Saos-2 cells by Western blot analysis. Wild-type p53 expression led to strong induction of the p21 gene while the R270?C mutant failed to induce p21 ( Figure  3b ). The T122?L allele exhibited a low level of induction compared to wild-type p53. The difference between ectopic and endogenous gene results may be due to the high copy number of the luciferase reporter and location on a plasmid, which might overestimate the transactivation potential of p53 alleles that retain partial activity. 
The T122?L allele exhibits novel transactivation properties in a yeast-expression assay
As shown above, the T122?L allele falls into the category of p53 mutant proteins that retain partial activity (Ludwig et al., 1996) . However, contrary to previously described mutants that showed partial function (Blagosklonny et al., 2001 ), it appears to retain activity with the weaker Bax promoter but not with the stronger p21. Furthermore T122?L is the first example of a tumor hotspot mutant that exhibits this type of altered transactivation function as a result of an amino acid change in the L1 loop -S2 strand region, which is part of the highly conserved domain II. Interestingly, similar functional results were reported for the human S121?F p53 mutant (corresponding to S118 in mouse p53), also in the L1 loop (Freeman et al., 1994; Kaeser and Iggo, 2002) . However, S121?F has never been found in tumors and its ectopic expression led to enhanced apoptotic response compared to wild-type p53 (Saller et al., 1999) .
These results prompted us to characterize extensively the in vivo transactivation capacity of the T122?L Figure 3 (a) T122?L transactivation activity in MEFs. MEF cells were transfected using the FuGENE TM 6-transfection reagent, with 2 mg of p53 expression vector and 4 mg of reporter plasmid and recovered after 48 h. Relative average luciferase units and standard deviations for at least three independent experiments are presented. The six promoters tested are indicated. T122?L p53 transactivation activity is compared to wild-type p53 and the R270?C mutant. (b) p53 expression levels and induction of the p21 gene in Saos-2 transient transfectants. Protein extracts were prepared 24 h after transfection. p53 and p21 levels (pAb-C19) were determined by Western blot analysis
protein with a large variety of REs using a yeast-based reporter system. Previously, three yeast strains were developed that contained a copy of the ADE2 color (red/white) reporter gene whose transcription was dependent on p53 protein binding to an upstream RGC, Bax or p21 RE (Flaman et al., 1995 (Flaman et al., , 1998 .
More recently we developed a system in yeast that provides opportunities to examine functional features of mutants in the DNA binding domain. p53 expression is controlled by a rheostatable GAL1 promoter (rather than a strongly expressing promoter) so that relative p53 transactivation ability on various REs can be assessed . This system was adapted to study the effects of the mouse T122?L allele on transactivation and the number of REs examined was extended to 12 using isogenic strains each containing a different p53 RE (see Table 1 ). While transactivation could be examined at reduced levels of expression, higher expression of the T122?L allele from the GAL1 promoter completely prevented yeast growth, irrespective of the strain background and the affinity for the p53 RE in the ADE2 reporter gene ( Figure 4 , Table 1 ). Under the same conditions expression of wild-type mouse p53 protein resulted in small colonies (not shown), as did human p53 protein (similar to our previous studies ). In contrast, the non-functional mutant allele R270?C had little effect on growth (data not shown). We also constructed yeast expression vectors with p53 under the control of the moderately expressed, constitutive ADH1 promoter. As expected from other reports (Scharer and Iggo, 1992) , wild-type p53 protein did not affect yeast growth at this level of expression while the T122?L allele prevented growth (data not shown). This strong growth-inhibiting phenotype is similar to that found for supertrans/toxic p53 alleles which we previously described .
We also evaluated the transactivation potential of the T122?L allele with respect to nine human and three murine p53 REs at low levels of induction from the GAL1 promoter. Each of these response elements, which belong to the p53 consensus but differ in nucleotide sequence (el-Deiry et al., 1992) , were derived from the regulatory regions of p53-regulated genes involved in cell cycle arrest, DNA repair and apoptosis induction. While the human REs may not be identical to those in the homologous mouse genes, they provide Figure 4 Transactivation potential of wild-type and T122?L mutant p53 proteins under condition of variable expression in the yIG397, yPHp21, and yPHbax strains. GAL1::p53 expression vectors were transformed into strains containing 3xRGC, BAX and p21::ADE2 reporters. Transformants were streaked out for single colonies on plates containing 2% raffinose as the carbon source plus the indicated amounts of galactose inducer. A low amount of adenine (5 mg/l) in the plates allows the assessment of p53 dependent transactivation (white/pink vs red colonies). When grown on medium lacking galactose, all colonies are red. On 0.002% galactose T122?L is defective for transactivation with 3xRGC (red colonies compared to white colonies obtained with wild-type p53 transformants), but it exhibits enhanced activity with both p21 and BAX on the 0.002% galactose plate (pink colonies vs the red colonies with wt p53). On 0.032% wt p53 efficiently induces all three promoters, while this level of expression prevents growth of T122?L transformants Independent yeast transformants containing the p53 expression vector were streaked for single colonies on plates containing raffinose (which leads to a higher basal level of GAL1 expression compared to glucose) plus different amounts of the galactose inducer (e.g., see Figure 4 ). Growth and levels of transactivation, indicated by red, pink or white colonies, were determined and compared to wild-type p53 expression (Table 1) . Transactivation analysis at low expression levels revealed differences in activity of wild-type p53 with the various REs. For example, transactivation with the GADD45, AIP1, p21-5' REs was observed at lower levels of p53 expression than with the p21-3', BAX, and MDM2 REs. Under conditions of high expression (0.032% galactose) where cells containing T122?L do not grow, wild-type p53 showed detectable transactivation with all REs. However, transactivation of the PIG3 and IGF -BP3 REs by wild-type p53 was reduced even at 0.3% galactose (i.e., pink colonies) (data not shown). It is worth noting that human and murine wild-type p53 (that share an overall 89% identity in the DNA binding domain) showed the same relative differences in transactivation capacity with these REs (data not shown).
Multiple differences were noted between the T122?L mutant and wild-type alleles that were revealed only at various low levels of expression. Surprisingly, transactivation was enhanced for the REs p21-5', GADD45, BAX, IGF -BP3-boxA and possibly PIG3, while it was reduced but clearly detectable with the PCNA, AIP1 and m-FAS REs. Wild-type levels of transactivation were observed with cFOS. Finally, there was no transactivation (colonies remained red) with the p21-3', 3xRGC, and MDM2 REs, indicating a loss of binding to these elements. The increased transactivation with some p53 REs did not correlate with the relative transactivation capacity of wild-type p53 protein towards the various elements. In fact, transactivation was enhanced with both strong (e.g., GADD45, p21-5') and weak (e.g., BAX, IGF -BP3) p53REs.
Since T122?L showed both reduced and enhanced functional activity it is unlikely that differences in protein stability explain the transactivation results. In a separate study with wild-type p53, we established that the amount of p53 is directly proportional to the amount of inducer, so that differences in the levels of galactose required to detect transactivation can be used to estimate relative transactivation capacity towards different REs (Inga et al., in preparation) . Based on the amount of p53 required for transactivation, T122?L is *3 times less active than wild-type p53 for transactivation at the AIP1 response element and two times less active with PCNA and mFAS. Interestingly, T122?L showed partial function (pink colonies) with this latter RE at low expression, but transactivation did not improve by increasing the protein amount. The mutant protein was *5 and three times more active with the Bax and p21-5' REs, respectively. The largest difference, *10-fold increase, was found with IGF-BP3. This is one of the weakest REs with wild-type p53 but among the strongest with T122?L. The sequence of IGF -BP3 RE (5' AAACAAGCCacAACATGCTT-3') has two mismatches from the consensus, both at the first position of the p53-monomer binding sites. It is unclear how the T122?L change can improve p53 binding to IGF -BP3. Molecular modeling of the equivalent human T122?L change predicted that the mutant protein would be non-functional .
Since most of the functional assays have been performed in isogenic strains that differ only by the small RE sequences, we conclude that the T122?L amino acid change leads to altered DNA binding specificity towards many REs.
Discussion

Novel features of the T122?L mutation revealed in mammalian and yeast cells
To better understand the importance of the unusual hotspot T122?L change in p53, we utilized a variety of approaches to assess the functional consequences of this mutation. These approaches in yeast and mammalian cells can be used to characterize the many functionally altered p53 alleles that are likely to appear in human tumors.
Our results indicate that the hotspot T122?L mutant protein has novel functional features relative to wild-type and other p53 hotspot mutant proteins. The mutant protein exhibited transactivation in luciferase assays, induced partial cell cycle arrest (but not apoptosis) in response to UV radiation, and was poorly tolerated when ectopically over-expressed in Saos-2 cells. These results in mammalian cells suggest a separation of functions since there was loss of apoptosis induction. This specific change in apoptotic response has also been described for a small number of p53 mutations that when over-expressed in tumor cell lines exhibited normal or partial activity toward the p21 promoter in reporter assays, but lacked transactivation of the Bax promoter (Blagosklonny et al., 2001; Ludwig et al., 1996) . While the induction of p21 can be sufficient for cell cycle arrest, the p53-dependent apoptotic response appears to require the concerted activation of several genes including Bax (Munsch et al., 2000) . Transactivation by T122?L p53 differs from these rare partial function mutations in that it has no activity towards p21 in MEFs or has greatly reduced activity in Saos-2 cells towards the p21, but shows wild-type activity with the Bax promoter in both cell lines. Yet, its ectopic expression only leads to G1 arrest and there is no apoptotic response.
Results obtained with over-expressed p53 alleles at non-physiological levels of protein must be viewed cautiously, especially in light of the complexity of p53 T122?L p53 mutational hotspot A Inga et al responses and their regulation, and the activation hierarchy of the many target genes (Vogelstein et al., 2000; Zhao et al., 2000) . For example, p53 REs often deviate from the loose consensus sequence in terms of the actual sequence and the number and the arrangement of elements, resulting in variation in transcriptional activation (Szak et al., 2001; Thornborrow and Manfredi, 1999; Wieczorek et al., 1996) . In addition, the level of p53 expression, the extent of specific post-translational modifications in the pool of nuclear p53 proteins and the availability of cofactors might affect the biological outcome of the p53 response by establishing further discrimination between target genes (Thornborrow and Manfredi, 2001 ). The yeast p53 functional assay with moderate p53 expression under the ADH1 promoter has also been used to characterize many tumor alleles and identify p53 mutant forms retaining function with specific REs (Campomenosi et al., 2001; Flaman et al., 1998) . While several alleles appeared wild-type with p21 and mutant with Bax RE, the opposite phenotype was never observed. In addition, none of these mutants appeared to affect yeast growth.
The novelty of the T122?L mutant phenotype led us to characterize the transactivation potential of this allele using the rheostatable p53 expression system developed in yeast . This assay previously revealed several p53 mutations that are toxic in yeast at the moderate expression levels found with the frequently used constitutive ADH1 promoter . At low expression levels, the toxic mutants often exhibited enhanced transactivation and altered promoter specificity. The T122?L allele is similar to these supertrans/toxic mutants. It is located in the conserved domain II and it prevents growth of yeast, even at moderate levels of expression.
The transactivation analysis at various low levels of expression identified numerous changes of the T122?L protein relative to wild-type p53. These included enhanced or supertrans activity for several REs, and reduced or no transactivation for others (Table 1) . For example, the human V122?A mutant allele (corresponding to V119 in mouse p53) showed a transactivation pattern similar to T122?L (unpublished results), although there were increased activities with hFAS and mFAS REs. V122?A was wild-type for growth suppression in Saos-2 cells, and it has never been found in tumors .
A comparison of transactivation results showed a good correlation for activation of BAX, c-Fos and RGC p53 REs by T122?L in yeast and mammalian cells (Figure 3 and Table 1 ), while there were differences with p21 and MDM2. However, the two p21 REs from the human p21 promoter were examined separately in yeast and opposite activities were found with T122?L (i.e., enhanced and defective transactivation). The contribution of both elements to the activity of the complete promoter is uncertain. The yeast results suggest that efficient activation of the p21 promoter requires the interaction of p53 with both REs. Interestingly, the p21-3'RE is about 1 Kb closer to the transcription start site and may have an important role in stimulating chromatin modifications near the TATA box (Espinosa and Emerson, 2001 ). In the case of MDM2 only one of two REs found in the p53-responsive intronic promoter (Zauberman et al., 1995) was tested in yeast. It is possible that T122?L retains activity with the other MDM2 RE and hence manifests activity with the complete promoter in mammalian cells. Gene expression profiling in mouse skin cells at physiological levels of p53 expression might be informative in characterizing how the T122?L mutations alters the pattern of expression of p53-regulated genes.
Preference for the T122?L p53 mutation in Xpc
Several factors can influence the appearance of mutation hotspots in genes. These include (i) the likelihood that a nucleotide(s) is damaged; (ii) the ability of one or more DNA repair systems to detect and process the damage; (iii) the miscoding potential of the lesion and (iv) the functional consequences of the mutation (Holmquist and Gao, 1997) . Given the wellestablished role of p53 in tumor suppression, the functional consequences of mutations in this gene are expected to significantly contribute to selection (Rodin et al., 1998) . The predominance of p53 tumor mutations located in the DNA-binding domain and their predicted effect in reducing or preventing DNA binding strongly supports the view that p53 transactivation function is critical to tumor suppression (Ko and Prives, 1996) . Several p53 mutation hotspots have been identified in tumors (Hernandez-Boussard et al., 1999) , and some have been associated with specific DNA changes such as DNA damage or methylation of CpG sequences (Hussain and Harris, 1999) . Some hotspots that are associated with tumorigenesis result in gain of function (Lee et al., 2000; Murphy et al., 2000) . Mutations in p53 are frequently observed in nonmelanoma skin cancers, particularly in squamous cell carcinomas, in which p53 mutant clones can be detected in normal and pre-malignant cells (Brash and Ponten, 1998) . p53 mutational hotspots in skin tumors have revealed a distinctive fingerprint that is a hallmark of UV radiation-induced mutagenesis, namely tandem mutations at dipyrimidine sites (Sage et al., 1996) . It has been proposed that mutation of one p53 allele in cells exposed to chronic UV radiation confers a phenotypic advantage due to a partial inhibition of the wild-type protein leading to less apoptosis of damaged 'sunburn' cells (Brash et al., 1996) .
The T122?L hotspot in Xpc 7/7 p53 +/7 mice is clearly different from other p53 mutation hotspots and is likely the result of altered DNA repair and/or selection for the unique function(s) of this allele. Defective nucleotide excision repair (NER) increases the risk of UVB-induced squamous cell carcinomas in mice . While the T122?L amino acid change is infrequent in Xpa
Nahari and EC Friedberg, unpublished observations), it is the predominant p53 mutation hotspot in skin cancers induced by UVB irradiation in Xpc 7/7 p53 +/7 mice . This difference could result from a specific requirement for XPC protein for the repair of a minor type of UV-induced lesion at a nondipyrimidine site. Alternatively, or additionally, the selective pressures for p53 inactivation during skin carcinogenesis might differ between the Xpc-and Xpadefective mice. Xpc 7/7 cells are defective only in global genome repair (GGR) while Xpa 7/7 mutants are also defective in transcription-coupled repair (TCR) (Volker et al., 2001) .
Stalled RNA polymerase at the site of a lesion, inhibition of transcription and/or prolonged association of p53 proteins with TFIIH might contribute to p53 activation and induction of apoptosis. Differences have been observed in the cellular responses of Xpa and Xpc mutants to UV radiation. While large amounts of p53 accumulate in the nucleus and enhanced levels of apoptosis are observed in UVirradiated Xpa 7/7 keratinocytes, the apoptotic response of Xpc 7/7 keratinocytes is similar to that observed in wild-type cells (Wijnhoven et al., 2000) . Moreover, like wild-type cells, UVB-irradiated Xpc
but not Xpa 7/7 keratinocytes can progress through S phase, a stage of the cell cycle where p53 function might be reduced (Gottifredi et al., 2001) . However, the defect in GGR coincides with subsequent arrest in G 2 , likely resulting from persistent DNA damage (van Oosten et al., 2000) .
Given the potential role of p53 in affecting DNA repair (Offer et al., 2001; Smith et al., 2000) , p53 mutations that result in less apoptotic activity while retaining DNA repair stimulation and cell cycle control may have a higher likelihood of being oncogenic. Interestingly, the transactivation results with T122?L in yeast (Table 1) showed reduced activity with the RE of both AIP1 and mFAS, two important genes for UV radiation-induced apoptosis in skin cells (Hill et al., 1999; Oda et al., 2000) , and slightly enhanced activity with the RE of Gadd45 gene, that instead contributes to DNA repair (Smith et al., 2000) .
The reasons for the genetic background contributing to the appearance of the T122?L hotspot are not obvious. However, it is interesting to speculate on this possible contribution in light of the following observations: (1) the levels of p53 protein produced in wildtype and various DNA repair deficient mouse mutants in response to UV are different; and (2) specific responses such as apoptosis can be enhanced at high levels of p53 (Lane, 2001; Zhao et al., 2000) . In order to induce skin cancer, mice were chronically UVirradiated. This is expected to result in p53 stabilization/activation and subsequent downstream p53-regulated responses. Mice with the following six genotypes were examined: wild-type, p53 +/7 , Xpc Takeuchi et al., 1998) (Nahari and Friedberg, unpublished results) . Since the amount of unrepaired damage influences the extent of p53 induction, the Xpa 7/7 cells would have the highest levels of p53 and apoptosis. The p53 levels would be expected to be reduced in Xpc 7/7 cells and somewhat lower in wild-type cells where repair is most extensive. The appearance of the T122?L p53 mutation in the Xpc 7/7 p53 +/7 background might result in greater viability compared to Xpa 7/7 p53 +/7 cells because of less p53 protein and reduced ability to induce apoptosis by the mutant protein. The partial capacity by T122?L for cell cycle arrest and DNA replication/ repair functions might further reduce p53-independent apoptosis. Since the mutation appears to be recessive, there would be no selective advantage of a T122?L mutation in a p53 +/+ background. There have been only two cases of tumor-associated T122?L mutations in Xpc 7/7 p53 +/+ mice and in both the other allele had an independent inactivating mutation . In p53 +/+ cells there would be a strong selective pressure for dominant-negative, non-functional p53 mutations (such as R270?C) that may also affect p53-independent (e.g., p73-mediated) apoptosis. Interestingly, although the R270?C mutation is frequent in UVB-induced skin tumors from wild-type, and p53
or Xpa 7/7 mice, it was not found in the Xpc 7/7 p53 +/7 background Takeuchi et al., 1998) .
Implications of the T122?L mutation
We have determined that the T122?L mutant p53 is altered in its ability to recognize and transactivate a variety of test REs and have shown that its activity in the yeast functional assay is different from any of the previously studied hotspot tumor p53 alleles. Our results suggest that it is unlikely that the high incidence of T122?L mutations in tumors is solely the result of specific DNA damage, a defect in DNA repair, and/or a reduction in wild-type p53 gene dosage. The altered DNA binding affinity and specificity of the T122?L mutant protein suggests that it would lead to an altered pattern of expression of downstream p53-regulated genes in vivo in tumor cells and that this contributes to its selection. These results suggest that other p53 tumor mutations may also reflect functional changes that are uniquely advantageous in the tissue in which they arise. In this regard, it is interesting that in breast cancers identified in BRCA1 families, novel p53 mutations have been detected (Crook et al., 1998) , some of which have subtle transactivation defects (Inga and Resnick unpublished) .
We propose that the yeast functional assay with inducible p53 expression is a relevant and sensitive screening tool for evaluating p53 tumor mutations that retain partial function. Transactivation analysis with variable expression of p53 using different REs under isogenic conditions provides for broad characterization of the relative transactivation capacity of p53 alleles. This information may be valuable for structure/ function studies, tumor diagnosis, prognosis and clinical intervention. When combined with our recent delitto perfetto system for rapid in vivo, site-directed T122?L p53 mutational hotspot A Inga et al mutagenesis (Storici et al., 2001) , this assay may prove useful for developing a detailed functional classification of tumor-associated p53 alleles.
Materials and methods
Plasmids, MEF and Saos-2 cell transfections, growth suppression assays, luciferase assays, and Western blots
The mouse wild-type p53 cDNA and the T122?L and R270?C mutant cDNAs were cloned into plasmid pCI-Neo (Promega, Madison, WI, USA) under control of the strong constitutive CMV promoter. These vectors were used for transient transfections in MEFs and for all experiments in Saos-2 cells. p53 7/7 and p53 +/+ MEFs were derived from 12-day-old embryos by culturing homogenized samples in DMEM with 10% fetal calf serum at 378C under 5% CO 2 . For growth suppression assays, MEF cells were infected by the retroviral vector pBabe -PURO expressing mutant p53 alleles under the LTR promoter. Puromycin-resistant colonies were selected. For the luciferase assays, 8610 5 cells were plated 24 h before transfection. The cells were then transfected using the FuGENE TM 6 transfection reagent (Roche, Indianapolis, IN, USA), 2 mg of pCI -Neo p53 expression vector and 4 mg of reporter plasmid and recovered after 48 h. Luciferase activity from 10 ml of cell lysates was assayed with the Luciferase assay system (Promega) using a Rosysenthos Lucy 2 type luminometer.
The osteosarcoma derived p53 null cell line Saos-2 was obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were cultured in McCoy's 5A medium with 15% FBS serum (Life Technologies, Grand Island, NY, USA). T25 cm 2 cell cultures flasks were seeded and transfected at 60 -80% confluence by the lipofectamine reagent (Life Technologies). For stable transfections, 1 mg of purified plasmid DNA was used. Cells were selected by adding G418 (Life Technologies) at 0.5 mg/ml after one day of recovery in complete medium following removal of lipofectamine. Colonies were stained with Coomassie Blue after 2 -3 weeks. Independent stable transfectant clones were obtained by limiting dilution in 96-well plates. Luciferase assays were performed using 20 ng of p53 expression plasmid and 500 ng of reporter vector in 12 well-plate clusters. Plasmids pGL1012, pGL1138 and pGL -NA containing a 370 bp fragment of the human BAX promoter, a 2.3 kb region from the p21 promoter, and the MDM2 -P2 promoter regulating the luciferase gene, respectively, were kindly provided by Dr Moshe Oren. Plasmid PG13 containing the luciferase gene under p53 control through 13 copies of the RGC sequence was kindly provided by Dr Bert Vogelstein.
Cells were recovered after 24 h, lysed, and protein concentration was measured with the Bradford assay (Biorad, Hercules, CA, USA) according to the standard protocol. Luciferase activity was measured with the Luciferase Assay System (Promega, Madison, WI, USA) using the single photon monitor program in a scintillation counter (Beckmann, Irvine, CA, USA). After subtraction of the blank reading, arbitrary light units relative to 1 ng of protein extract were determined. The same or similarly obtained protein extracts were used for Western blot analysis. Precast SDS -PAGE gels (PAGE -ONE, Owl Separation Systems, Portsmouth, NH, USA) were used for electrophoresis. Proteins were transferred to PVDF membrane (Immobilon-P, Millipore, Bedford, MA, USA) using a semi-dry electroblotter (Owl Separation Systems) according to instructions. p53 was detected using both pAb1801 and DO-1 monoclonal antibodies (Santa Cruz Biotech, Santa Cruz, CA, USA) at a 1 : 2000 dilution. p21 was detected using C-19 polyclonal antibody at a 1 : 1000 dilution (Santa Cruz). Immunodetection was performed using the ECL kit (Amersham, Cleveland, OH, USA) according to protocol.
Apoptosis and cell cycle assays in MEFs p53
7/7 MEF cells were stably infected using the retroviral vector pBabe -PURO that was empty or expressed either the T122?L or the R270?C mutant proteins under the LTR promoter. 1610 6 cells per 15 cm 2 dish were plated and were irradiated or mock-treated 24 h later. The cells were harvested 48 h after treatment. Determination of death and DNA content was performed by double staining the cells with 7-AAD (Molecular Probes) and Hoechst (Molecular Probes). Levels of fluorescence staining were assessed by flow cytometry (FACScan Becton Dickinson Immunocytometry Systems, San Jose, CA, USA).
Yeast strains, plasmids, media and reagents
The haploid S. cerevisiae strain yIG397 (Mata ade2-1 leu2-3,112 trp1-1 his3-11,15 can1-100 ura3-1 URA3 3xRGC::CY-C1::ADE2) (Flaman et al., 1995) contains an integrated copy of ADE2 under control of a minimal CYC1 promoter. Three copies of the human p53 response DNA element found at the ribosomal gene cluster are inserted in the upstream region of the promoter. Thus, ADE2 is under p53 transcriptional control so that transactivation by p53 mutant proteins can be easily scored based on the color of yeast transformants on suitable plates. Colonies expressing wild-type p53 grow as adenine prototrophs yielding white colonies on plates containing a limiting amount of adenine while small red colonies appear when a nonfunctional p53 is expressed. The haploid strains, yPH-p21 (Mata ura3-52 lys2-801 ade2-101 trp1 -D63 his3 -D200 leu2 -D1, URA3::p21-RE::pCY-C1::ADE2) and yPH-bax (Mata ura 3-52 lys2-801 ade2-101 trp1 -D63 his3 -D200 leu2 -D1 URA3::bax-RE::pCY-C1::ADE2) (Flaman et al., 1998) allow the evaluation of p53 transactivation function as in yIG397, but with the p21 and BAX p53 REs controlling ADE2 transcription, respectively. In order to assess the transcriptional activation of the same ADE2 reporter gene at a fixed chromosomal locus as a function of specific p53 REs, the haploid strain yIG397 was modified as follows. A ura3 mutant that had popped out the ADE2 reporter gene at the URA3 locus was obtained. The ade2-1 gene was deleted by a PCR-based method and a promoterless wild-type copy of the ADE2 open-reading frame was integrated replacing the ade2-1 locus. Isogenic derivatives of this strain, identified as yAFM-RE, each containing a minimal CYC1 promoter that replaces the promoter of the ADE2 open-reading frame fused to a different p53 RE, were constructed. Expression of wild-type p53 in the yAFM strains results in the growth of white colonies on plates containing a limiting amount of adenine, since p53 stimulates ADE2 transcription, while small red colonies appear when nonfunctional p53 is expressed. All the p53 response elements tested in this study are listed in Table 1 . The sequence of each response element and a detailed description of the strain construction will be described elsewhere (Inga et al., in preparation) .
Plasmids pTGmp and pTAmp are yeast centromeric expression vectors for the mouse wild-type p53 under the control of the GAL1,10 and ADH1 promoters, respectively. They were constructed from plasmid pLS89 (Flaman et al., 1995) by replacing the human p53 cDNA with the mouse homologue to obtain pTGmp and then replacing the GAL1 promoter with the ADH1 promoter to obtain pTAmp. The T122?L and R270?C mutations were cloned in pTGmp and pTAmp from the pCI-Neo vectors.
Yeast strains were cultured in 1% yeast extract, 2% peptone, 2% dextrose (YPD) or in YPD medium containing 200 mg/l adenine (YPDA) or on selective medium. p53 transactivation was generally determined in synthetic medium containing 5 mg/l adenine. Synthetic medium containing 2% raffinose (Sigma, St. Louis, MO, USA) as carbon source and variable concentrations of galactose was used to test transactivation and growth inhibition by various levels of p53.
